Clinical Trial and Stability Batch Manufacture to Commence in Q4 2025 Clinical Testing in a Number of Indications Including Microcystic Lymphatic Malformations and Venous Malformations, among others ...
Palvella Therapeutics reports progress in clinical trials for QTORIN™ rapamycin, exceeding patient enrollment and anticipating significant results in upcoming years. Net loss of $8.2 million for the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results